Capricor Therapeutics (FRA:4LN2) Short-Term Capital Lease Obligation : €0.71 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics Short-Term Capital Lease Obligation?

Capricor Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.71 Mil.

Capricor Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (€0.68 Mil) to Dec. 2023 (€0.69 Mil) and increased from Dec. 2023 (€0.69 Mil) to Mar. 2024 (€0.71 Mil).

Capricor Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€0.37 Mil) to Dec. 2022 (€0.64 Mil) and increased from Dec. 2022 (€0.64 Mil) to Dec. 2023 (€0.69 Mil).

Capricor Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Capricor Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Short-Term Capital Lease Obligation Chart

Capricor Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.37

0.64

0.69

Capricor Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.65	0.65	0.68	0.69	0.71

Capricor Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Capricor Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics (FRA:4LN2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CAPR:USA

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics (FRA:4LN2) Headlines

No Headlines